Open Access<p>FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer</p>
Author(s) -
Martina Catalano,
Raffaele Conca,
Roberto Petrioli,
Monica Ramello,
Giandomenico Roviello
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s267393
Subject(s) - folfiri , medicine , folfox , folfirinox , gemcitabine , oncology , progression free survival , chemotherapy , clinical endpoint , regimen , pancreatic cancer , irinotecan , gastroenterology , cancer , oxaliplatin , randomized controlled trial , colorectal cancer
Several progresses have been achieved for first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with Gem-NabP and FOLFIRINOX extensively used as standard first line regimens. However, the best second-line chemotherapy choice after progression is still not completely defined. The aim of this study is to compare effectiveness and safety of two possible second-line therapeutic options, FOLFOX and FOLFIRI, after progression to Gem-NabP.